| Entry |
|
|---|
| Name |
Brentuximab vedotin (USAN);
Adcetris (TN)
|
|---|
| Product |
|
|---|
| Formula |
C6476H9930N1690O2030S40. (C68H105N11O15)n
|
|---|
| Activity |
Treatment of Hodgkin's lymphoma, CD30-positive hematologic malignancies [DS: H00007]
|
|---|
| Remark |
|
|---|
| Comment |
CD30-directed antibody-drug conjugate to Monomathyl auristatin E [DR: D09691]
monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
hsa04060 Cytokine-cytokine receptor interaction | |
|
|---|
| Interaction |
Genomic biomarker: CD30 [HSA: 943] expression
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC12 Brentuximab vedotin
D09587 Brentuximab vedotin (USAN)
Target-based classification of drugs [BR:br08310]
Cytokine receptors
TNF receptor family
TNFRSF8 (CD30) [HSA:943] [KO:K05145]
Brentuximab vedotin [ATC:L01XC12]
D09587 Brentuximab vedotin (USAN)
Antineoplastics [BR:br08308]
Molecularly targeted agents
Monoclonal antibody
Brentuximab [ATC:L01XC12]
D09587 Brentuximab vedotin (USAN)
 |
|---|
| Other DBs |
|
|---|
